Medicilon Appoints Dr. Xiaodong Zhang as VP, Preclinical Research Manager

著者：   アップロード：2017-09-13  閲読回数：

Medicilon is delighted to announce that Dr. Xiaodong (Mark) Zhang has joined us to further develop the growing Preclinical Research accounts.  Dr. Zhang comes with a wealth of experience within this field.

Picture of Dr.zhang

Dr. Zhang was the VP of Preclinical Research, Deputy Director of Department of Health Toxicology, SMMU; Deputy Director of Center for Evaluation of Drug Safety, SMMU; Drug Reviewer of Center for Drug Evaluation , CFDA and expert for Drug Consulting, Center for Drug Evaluation , CFDA.

Just as Dr. Chunlin Chen, CEO of Medicilon, said, "I’m confident that Mark will play a key role in providing and implementing high quality solutions for our clients."

上の：Innovative Research and Development Services Professional Committee established

下に：Welcome Dr. Wenxin Dong to Join the Department of Efficacy